Undercurrent of Management Failure, page-5

First 5 Last

SA1588

432 Posts.

02/11/17

11:34

Post #: 28432353

Originally posted by birdman29 ↑

Column 1 Column 2

1 23 October 2015 Managing Director Appointment Terms

ASX release
23 October 2015

MANAGING DIRECTOR APPOINTMENT TERMS

Further to its announcement on 15 October 2015 and in accordance with Listing Rule 3.16.4, nearmap Ltd (ASX:NEA) advises that the following material terms have been agreed with respect to Dr Newman’s appointment as Managing Director.
Dr Newman will receive an annual base salary of A$520,000, inclusive of statutory superannuation. In addition, he will be entitled to a discretionary bonus of up to 100% of annual base salary for the two year period to 30 June 2017, payable pro rata over his period in office on the achievement of performance criteria to be set by the Board.
Subject to shareholder approval to be sought at the Company’s 2015 Annual General Meeting (AGM), Dr Newman will be issued 3 million Director Options, each Director Option having an exercise price that is 43% above the closing Share price of the Company’s quoted Shares on ASX the day prior to the Meeting, vesting in equal tranches of 1,000,000 Director Options on the dates that are 12, 24 and 36 months from the date of issue and expiring 48 months from the date of issue.
A one month notice period will apply for the first six months of the Managing Director’s role, reverting to a six month notice period from 15 April 2016.

Dr Newman will be re-locating to Sydney from Perth. The Company has agreed to cover the cost of the lease on an apartment in Sydney for Dr Newman until 30 June 2016.
-ends-

Expand

This suggests the CEO has a direct personal interest to not announce positive news prior to the AGM. The share price will drift lower until the AGM. His option price will be set at 43% above the price prior to the AGM and the announcement of the positive news. The reverse also holds. The CEO has a direct personal interest to announce negative news prior to the AGM so the share price reflects that negative news.

Birdman's quote applies to the 2015 AGM. I wonder if it also applies to the 2017 AGM. It could explain why there is no update on sales in the US.

NEA Price at posting: 58.0¢ Sentiment: Buy Disclosure: Held

2 Upvote

0 Great analysis

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

HotCopper Highlights: Your most watched stocks for Week 47, 2024

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

SIG

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game

There are more pages in this discussion • 11 more messages in this thread...

First 5 Last

Add NEA (ASX) to my watchlist

Undercurrent of Management Failure, page-5

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

HotCopper Highlights: Your most watched stocks for Week 47, 2024

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Sales growth pushes Lovisa's fortunes (and shares) upwards

This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game

Featured News